NCT00544986已完成4 期
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 主要终点
- 1. Tolerability(safety) 2.Efficacy (a) Time to tumor progression TTP (b) Objective Response (OR) Rate (c) Symptom Evaluation
研究概览
简要总结
The overall objective of the clinical study is to assess the tolerability and clinical efficacy of anastrozole in post-menopausal women with hormone sensitive advanced breast cancer in India.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Patients must be adult (age ≥ 18 years age) post-menopausal* women
- •Patients must be diagnosed with advanced breast cancer (histologically or cytological confirmation required) i.e. TNM stage III or IV disease (locally advanced or metastatic breast cancer) or locoregional recurrent disease, not suitable for treatment by local surgery or radiation therapy
- •Measurable or evaluable disease
- •Patients with ER/PR positive tumour or ER/PR unknown status
- •Patients must be suitable for endocrine treatment with anastrozole
- •Prior adjuvant chemotherapy or endocrine therapy for early breast cancer is allowed, provided such treatment was completed at least twelve months prior to study enrollment
- •Performance status 0-2 (As per WHO Classification)
- •Concurrent use of bisphosphonates is permitted.
- •Patients must give their written informed consent for participation in the study
排除标准
- •Patients with tumors known to be estrogen and progesterone receptor-negative.
- •Estrogen hormone replacement therapy, concurrently or within 6 weeks before randomization
- •Extensive visceral involvement (significant hepatic involvement, brain metastasis or pulmonary involvement > 50% of the lungs); serum liver enzymes SGOT and SGPT should be no greater than five times the upper limit of the reference range
- •Patients received bone marrow transplantation before randomization
- •Any concurrent medical illness (uncontrolled cardiac disease or diabetes mellitus) or laboratory abnormalities that would compromise safety or prevent interpretation of results
- •An estimated survival of less than 3 months from the start of Study drug treatment based on clinical judgment.
- •Any systemic investigational drug within the thirty days of enrollment into study
结局指标
主要结局
1. Tolerability(safety) 2.Efficacy (a) Time to tumor progression TTP (b) Objective Response (OR) Rate (c) Symptom Evaluation
次要结局
- Efficacy (a) Time to treatment failure TTF (b)Duration of Response DOR (c) Duration of Clinical Benefit
研究者
相似试验
已完成
2 期
Arimidex in McCune Albright SyndromeMcCune-Albright SyndromeNCT00055302AstraZeneca40
终止
4 期
Lansoprazole Preventing Gastroduodenal Stress UlcerationsPatients Undergoing Elective Coronary Artery Bypass GraftNCT00220909Temple University40
已完成
2 期
Anastrozole in Patients With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT01545336University of Pennsylvania18
已完成
不适用
Bioequivalency Study of Anastrozole 1 mg Under Fed ConditionsBreast CancerNCT01155089Roxane Laboratories32
已完成
2 期
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)Breast CancerNCT00081510Merck Sharp & Dohme LLC110